Joseph Group Capital Management Has $4.23 Million Stock Position in Amgen Inc. $AMGN

Joseph Group Capital Management reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 10.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,930 shares of the medical research company’s stock after selling 1,537 shares during the quarter. Joseph Group Capital Management’s holdings in Amgen were worth $4,232,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. Capital World Investors lifted its holdings in Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares during the last quarter. Vanguard Group Inc. increased its position in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares during the period. National Bank of Canada FI increased its position in Amgen by 237.7% during the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after buying an additional 863,216 shares during the period. Van ECK Associates Corp lifted its holdings in shares of Amgen by 71.8% during the third quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock worth $383,254,000 after buying an additional 567,400 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in shares of Amgen by 91.6% during the third quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock worth $221,607,000 after buying an additional 375,463 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $338.02 on Thursday. The company’s 50-day moving average price is $358.65 and its two-hundred day moving average price is $340.41. The firm has a market cap of $182.42 billion, a P/E ratio of 23.75, a P/E/G ratio of 3.36 and a beta of 0.47. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts anticipate that Amgen Inc. will post 22.16 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Analyst Ratings Changes

AMGN has been the topic of several research reports. Wells Fargo & Company upped their price target on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. The Goldman Sachs Group boosted their price objective on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Freedom Capital lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $356.62.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.